Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This trial explores the immunologic effects of vemurafenib (BRAF inhibitor) and cobimetinib (MEK inhibitor), administered alone and in combination, to patients with advanced BRAF V600E/K mutant melanoma.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Active systemic infection
Active autoimmune disease or history of known or suspected autoimmune disease
Active brain metastases or leptomeningeal metastases
Treatment with any immunomodulatory medication within 4 weeks of initiation of study therapy.
Positive test for hepatitis B virus
Positive test for hepatitis C virus
Positive test for human immunodeficiency virus (HIV)
Pregnant, lactating or breast feeding women
Localized radiation therapy within the last 14 days
History of malabsorption
No consumption of the following within 7 days prior to start of treatment:
History or evidence of cardiovascular risk
History or evidence of retinal pathology
Primary purpose
Allocation
Interventional model
Masking
0 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal